医师自制腔内移植物修复近肾、近内脏及Crawford IV型胸腹主动脉瘤的早期与中期结果
本研究为单中心、多臂、前瞻性综述,纳入首批44例使用医师改良的unitary manifold(UM)支架系统修复Crawford IV型、近肾、近内脏、近肾动脉及短颈(<10 mm)肾下腹主动脉瘤的患者。30天主要不良事件包括全因死亡、心梗、卒中、截瘫、肠缺血、呼吸衰竭和肾衰。技术成功44/44(100%),170根内脏血管全部成功插管并置入支架,无截瘫或院内死亡,1例死于动脉瘤相关缺血性卒中(2.3%),短暂性非临床显著脊髓缺血率4.5%。平均随访8.8个月,169/170桥接支架保持通畅,无I/III型内漏、移位或组件分离。结论认为UM早期和中期结果提示其可作为上述动脉瘤的可行选择,但经验有限,需进一步研究。
要点
- UM医师自制支架修复复杂腹主动脉瘤技术成功率高(44/44,100%)。
- 无截瘫或院内死亡,短暂性脊髓缺血率4.5%。
- 平均随访8.8个月,桥接支架通畅率169/170,无I/III型内漏。
核心结论
- UM医师自制支架修复Crawford IV型、近肾、近内脏、近肾动脉及短颈肾下腹主动脉瘤的早期和中期结果良好。
- 该技术可作为既往主动脉修复失败或病变向近端延伸的补救技术。
- 经验有限,需进一步研究后才能广泛推广。
研究设计与样本
- 单中心、多臂、前瞻性综述,纳入首批44例患者,在医师发起的研究性器械豁免下使用医师改良的UM支架系统。
- 修复对象包括Crawford IV型、近肾、近内脏、近肾动脉及短颈(<10 mm)肾下腹主动脉瘤。
- 主要终点为30天主要不良事件(全因死亡、心肌梗死、卒中、截瘫、肠缺血、呼吸衰竭和肾衰竭)的无事件率。
主要发现
- 技术成功44/44(100%),其中20/44(45.5%)有既往主动脉修复史。
- 170根目标内脏血管全部成功插管并置入支架(100%)。
- 无截瘫和院内死亡,1例死于动脉瘤相关缺血性卒中(2.3%),短暂性非临床显著脊髓缺血率4.5%。
- 平均随访8.8个月(范围0-36个月),169/170桥接支架保持通畅,1例因血栓事件行再干预。
- 未发生I型或III型内漏、移位或组件分离。
临床怎么用
- 对于Crawford IV型、近肾、近内脏、近肾动脉及短颈肾下腹主动脉瘤,UM医师自制支架可作为开放胸腹主动脉修复之外的可行选择。
- 该技术可用于既往腔内修复失败或病变向近端延伸的补救。
- 需注意经验有限,应谨慎选择患者并开展进一步研究。
局限性
- 单中心、小样本(44例),随访时间较短(平均8.8个月,范围0-36个月)。
- 经验有限,需进一步研究后才能广泛采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the present study, we reviewed the 30-day and 1-year clinical results of the use of the investigational unitary manifold (UM) stent graft system (Sanford Health, Sioux Falls SDak) for the repair of Crawford type IV, pararenal, paravisceral, juxtarenal, and short-neck infrarenal aneurysms (<10 mm). METHODS: The present study was a single-center, multiarm, prospective review of the first 44 patients who had undergone repair of Crawford type IV, pararenal, juxtarenal, and short-neck infrarenal aneurysms (<10 mm) using the physician-modified UM under a physician-sponsored investigational device exemption. The primary end point was freedom from major adverse events at 30 days, including all-cause mortality, myocardial infarction, stroke, paraplegia, bowel ischemia, respiratory failure, and renal failure. RESULTS: Technical success was achieved in all 44 patients (100%), with a large number of these patients having undergone previous aortic repair (20 of 44; 45.5%). All the intended 170 visceral vessels (100%) had been successfully cannulated and stent grafted. No episodes of paraplegia or in-hospital deaths were recorded. One patient had died of aneurysm-related ischemic stroke (2.3%). The rate of transient nonclinically significant spinal cord ischemia was 4.5%. At the last follow-up, one reintervention had been required owing to branch patency from a thrombotic event. Of the 170 bridging stent grafts, 169 have remained patent through a mean follow-up of 8.8 months (range, 0-36 months). No type I or III endoleaks, migration, or component separation in the investigational device has occurred. CONCLUSIONS: The early and midterm results with the use of the UM suggest it could be a viable option for the repair of Crawford type IV, pararenal, paravisceral, juxtarenal, and short-neck infrarenal aneurysms (<10 mm) without exposing patients to the increased risk of permanent spinal cord ischemia, renal failure, visceral vessel ischemia, or aneurysm-related mortality that results from open thoracoabdominal aortic aneurysm repair. The high technical success rate, in native and previous repairs, supports the utility of this device as a bail-out technique for failed endovascular aneurysm repair or proximal extension of disease after previous aortic repair. However, experience is limited, and this approach requires further study before widespread adoption.
引用
- Jorgensen BD, Malek M, VandenHull A, et al. A novel physician-assembled endograft for the repair of pararenal, paravisceral, Crawford type IV thoracoabdominal aortic aneurysms, and aneurysms requiring treatment after prior repair. J Vasc Surg. 2020. PMID: 32335306. doi:10.1016/j.jvs.2020.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。